Study shows Glaxo heart drug which failed trial has potential benefit

WASHINGTON (Reuters) - An experimental heart drug being developed by GlaxoSmithKline, which failed the main goal of a Phase III study of patients with chronic but well-treated heart disease, showed signs of potential benefit, the trial's co-leader said Sunday.

via Reuters: Health News Read More Here..